相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
Tingting Jiang et al.
ACTA PHARMACEUTICA SINICA B (2021)
ROS1-dependent cancers - biology, diagnostics and therapeutics
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2021)
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors
Georgina Meneses-Lorente et al.
INVESTIGATIONAL NEW DRUGS (2021)
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Entrectinib: A Review in NTRK plus Solid Tumours and ROS1+ NSCLC
James E. Frampton
DRUGS (2021)
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements
J. Delgado et al.
ESMO OPEN (2021)
PRO41 The Economic and Quality of Life impact of Entrectinib on CNS metastasis control
D. Tan et al.
VALUE IN HEALTH (2021)
TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Sun-Young Han
PHARMACEUTICALS (2021)
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Bo Mi Ku et al.
INVESTIGATIONAL NEW DRUGS (2020)
Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy
Paula Chu et al.
FUTURE ONCOLOGY (2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib
Neil Parrott et al.
AAPS JOURNAL (2020)
Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.
Christian Diego Rolfo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.
Ami Vijay Desai et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
Holger Fischer et al.
NEURO-ONCOLOGY (2020)
Evaluating entrectinib as a treatment option for non-small cell lung cancer
Jiyun Lee et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer
Paula Chu et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)
Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
T. John et al.
ANNALS OF ONCOLOGY (2020)
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
Elena Ardini et al.
ESMO OPEN (2020)
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
Wei Yan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Molecular characterization of cancers with NTRK gene fusions
Zoran Gatalica et al.
MODERN PATHOLOGY (2019)
Molecular profiling of ER plus metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.
Pedram Razavi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Entrectinib: First Global Approval
Zaina T. Al-Salama et al.
DRUGS (2019)
The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
Stephen P. Ducray et al.
CANCERS (2019)
LBA28Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2
R C Doebele et al.
ANNALS OF ONCOLOGY (2019)
Design, synthesis and biological evaluation of 3-(imidazo[1,2-a] pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors
Shengyang Cui et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients
R. Doebele et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Smoking Cessation: Is E-Cigarette better than classic Nicotine Substitutes? Reply
Reiner Hanewinkel
PNEUMOLOGIE (2019)
Determination of the efficacious Entrectinib exposures required for pathway inhibition and anti-tumor activity in a subcutaneous and intracranialTPM3-NTRK1mutant tumor model
Cecile C. de la Cruz et al.
CANCER RESEARCH (2019)
Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS
Mohamed W. Attwa et al.
CLINICA CHIMICA ACTA (2018)
Identification of [18F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging
Vadim Bernard-Gauthier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Dazhi Liu et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.
Ami Vijay Desai et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation
Mohamed W. Attwa et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
R. Doebele et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
S. M. de Boer et al.
ANNALS OF ONCOLOGY (2018)
A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human
Vadim Bernard-Gauthier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
Parag P. Patwardhan et al.
ONCOTARGET (2016)
Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells
Sanja Aveic et al.
ONCOTARGET (2016)
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model
Radhika Iyer et al.
CANCER LETTERS (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin
Laura M. McDonell et al.
HUMAN MOLECULAR GENETICS (2015)
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
Bryan D. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2014)
Inhibition of Irk-driven tumors by the pan-Trk inhibitor RXDX-101
D. Anderson et al.
EUROPEAN JOURNAL OF CANCER (2014)
ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
Dara L. Aisner et al.
MOLECULAR CANCER RESEARCH (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations
Filippo G. De Braud et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
Monika A. Davare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Bengt Hallberg et al.
NATURE REVIEWS CANCER (2013)
Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.
E. Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
The Selective Trk Inhibitor AZ623 Inhibits Brain-Derived Neurotrophic Factor-Mediated Neuroblastoma Cell Proliferation and Signaling and Is Synergistic With Topotecan
Peter E. Zage et al.
CANCER (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Crizotinib
Alice T. Shaw et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2010)
Fragment-based discovery of JAK-2 inhibitors
Stephen Antonysamy et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Recent advances in applications of liquid chromatography-tandem mass spectrometry to the ana lysis of reactive drug metabolites
Shuguang Ma et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2009)
Catalytic Transformations of Benzylic Carboxylates and Carbonates
Ryoichi Kuwano
SYNTHESIS-STUTTGART (2009)
Highly efficient synthesis of 5-benzyl-3-aminoindazoles
Paolo Orsini et al.
TETRAHEDRON LETTERS (2009)
Suzuki-Miyaura cross-coupling of benzylic phosphates with arylboronic acids
M McLaughlin
ORGANIC LETTERS (2005)
Suzuki-Miyaura cross-coupling of benzylic carbonates with arylboronic acids
R Kuwano et al.
ORGANIC LETTERS (2005)
分享论文
